Peter Heydemann Selected Research

Nonsense Codon (Nonsense Mutation)

1/2017

Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peter Heydemann Research Topics

Disease

2	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker) 01/2022 - 01/2017
2	Congenital Toxoplasmosis 12/2011 - 05/2006
1	Retinal Diseases 01/2022
1	Neurodevelopmental Disorders 01/2020
1	Rett Syndrome (Rett's Disorder) 01/2020
1	Optic Atrophy 12/2017
1	Mitochondrial Diseases (Mitochondrial Disease) 12/2017
1	Heart Failure 10/2015
1	Neurologic Manifestations (Neurological Manifestations) 03/2012
1	Toxoplasmosis 12/2011

Drug/Important Bio-Agent (IBA)

2	Pyrimethamine (Daraprim)FDA Link 03/2012 - 05/2006
2	Sulfadiazine (Sulphadiazine)FDA Link 03/2012 - 05/2006
1	eteplirsenIBA 01/2022
1	Methyl-CpG-Binding Protein 2IBA 01/2020
1	Oxidoreductases (Dehydrogenase)IBA 12/2017
1	Ferredoxin-NADP Reductase (Adrenodoxin Reductase)IBA 12/2017
1	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 12/2017
1	FlavoproteinsIBA 12/2017
1	NADP (NADPH)IBA 12/2017
1	Adenosine Triphosphate (ATP)IBA 12/2017
1	Reactive Oxygen Species (Oxygen Radicals)IBA 12/2017
1	Ferredoxins (Ferredoxin)IBA 12/2017
1	atalurenIBA 01/2017
1	Nonsense Codon (Nonsense Mutation)IBA 01/2017
1	VaccinesIBA 12/2011
1	AntibodiesIBA 12/2011

Therapy/Procedure

2	Therapeutics 10/2015 - 05/2006
1	Ventriculoperitoneal Shunt 01/2022